Technology licensing for base editing

Gain access to the Pin-point™ base editing platform

Would you like the opportunity to license a novel pathway in the development of cell and gene therapeutic programs? The Pin-point™ base editing system offers the specificity of base editing combined with the potential for multiplex gene editing capabilities, making it a very attractive technology for both cell and gene therapies.

Please contact us if you are interested in deploying base editing in your therapeutic pipeline for cell or gene therapy programs and one of our corporate development partners will be in touch.

Revvity enters license agreement with AstraZeneca

Read the announcement here

First Name *

Last Name *

Email *

Company / Institution Optional

Country *

Zipcode or Postal Code * Optional

Describe your project goal and/or difficulties your are experiencing Optional

By providing my personal data and clicking this button, I acknowledge that Revvity, Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy (available here).*

I would like to stay up-to-date about offers, products and services Optional

Literature Review - Base editing platform for simultaneous knock-in and multiple gene knockout

This literature review delves into an application of gene editing that diverges from the conventional paradigm.

Base editing with nuclease flexibility?

Learn more about Revvity's Pin-point™ base editing platform.

Increase the targeting scope and precision of next-generation gene editing technology

Explore the detailed data and analysis behind the Pin-point^TMbase editing system that shows the unique modularity of the platform.

Pin-point™ Technology Licensing is now part of Revvity’s portfolio

Accelerating therapeutic development and reach into the clinic